CCDC127: A Potential Drug Target for PDGF-BB, TGF-?1 and NF-??B

Target Name: CCDC127

NCBI ID: G133957

CCDC127

CCDC127: A Potential Drug Target for PDGF-BB, TGF-?1 and NF-??B

CCDC127, also known as OTTHUMP00000220452, is a protein that is expressed in various tissues throughout the body. It is a member of the CCDC family, which is known for its role in cell signaling and communication.

One of the main functions of CCDC127 is to regulate the activity of various signaling pathways that are involved in cellular processes such as cell growth, differentiation, and inflammation. It does this by interacting with a variety of different proteins, including the protein known as PDGF-BB.

PDGF-BB is a protein that is involved in cell signaling and growth, and it is a key signaling molecule for many different types of cancer. It is produced by the cells themselves, but it can also be found in the surrounding tissue and can be administered to cells as a treatment.

CDC127 is thought to be a potential drug target for PDGF-BB because it is involved in the regulation of PDGF-BB's activity. This is important because PDGF-BB has been shown to play a role in the development and progression of many different types of cancer, including breast, lung, and ovarian cancer.

In addition to its role in regulating PDGF-BB activity, CCDC127 is also involved in the regulation of many other signaling pathways that are important for cellular growth and development. It does this by interacting with a variety of different proteins, including the protein known as TGF-β1.

TGF-β1 is a protein that is involved in cell signaling and growth, and it is a key signaling molecule for many different types of cancer. It is produced by the cells themselves, but it can also be found in the surrounding tissue and can be administered to cells as a treatment.

CDC127 is thought to be a potential drug target for TGF-β1 because it is involved in the regulation of TGF-β1's activity. This is important because TGF-β1 has been shown to play a role in the development and progression of many different types of cancer, including breast, lung, and ovarian cancer.

In addition to its role in regulating TGF-β1 activity, CCDC127 is also involved in the regulation of many other signaling pathways that are important for cellular growth and development. It does this by interacting with a variety of different proteins, including the protein known as NF-kappa-B.

NF-kappa-B is a protein that is involved in cell signaling and inflammation. It is produced by the cells themselves, but it can also be found in the surrounding tissue and can be administered to cells as a treatment.

CDC127 is thought to be a potential drug target for NF-kappa-B because it is involved in the regulation of NF-kappa-B's activity. This is important because NF-kappa-B has been shown to play a role in the development and progression of many different types of cancer, including breast, lung, and ovarian cancer.

In conclusion, CCDC127 is a protein that is involved in the regulation of various signaling pathways that are important for cellular growth and development. It is a potential drug target for PDGF-BB, TGF-β1, and NF-kappa-B, which are all known to play a role in the development and progression of many different types of cancer. Further research is needed to fully understand the role of CCDC127 in cancer development and to identify potential strategies for its targeting.

Protein Name: Coiled-coil Domain Containing 127

The "CCDC127 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC127 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets